Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
Which FGFR inhibitor do you prefer for patients with cholangiocarcinoma and an FGFR2 gene rearrangement?
Would you always offer an FGFR inhibitor as second line therapy in these patients instead of a second line chemotherapy regimen?
Answer from: Medical Oncologist at Academic Institution
There are 2 FGFR inhibitors which are currently FDA approved (infigratinib and pemigatinib) and multiple other FGFR inhibitors in development. Futibatinib and derazantinib may get approved soon in the future as well. Looking at data and considering clinical trial differences, I am not sure there is ...
Sign in or Register to read more